Challenges and opportunities for hepatitis C drug development in HIV–hepatitis C virus-co-infected patients
Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope
Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control
Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir
Phenotypic susceptibility of HIV-2 to raltegravir
Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients
Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
Early antiretroviral therapy in HIV-1-infected infants, 1996–2008
Lessons learned in the deployment of a HIV counseling and testing management information system on a new project
Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission
Safety of efavirenz in the first trimester of pregnancy
Association of osteonecrosis and peripheral neuropathy in HIV-1-infected patients
Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient
The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis